卵黄状黄斑ジストロフィに伴う脈絡膜新生血管に対しベバシズマブ硝子体内注射を施行した1例

Intavitreal bevacizumab for choroidal neovascularization in a case of vitelliform macular dystrophy

要約　目的：卵黄状黄斑ジストロフィに伴う脈絡膜新生血管に対してベバシズマブ硝子体注射を行った1症例の報告。症例：23歳女性が右眼に突発した視力低下で受診した。8年前に眼球打撲を契機として眼科を受診し，卵黄状黄斑ジストロフィと診断された。当時の視力は左右眼とも1.2であった。所見：矯正視力は右0.5，左1.2であり，右眼黄斑部に網膜下出血があった。蛍光眼底造影で黄斑部に脈絡膜新生血管を示す所見があった。ベバシズマブの硝子体注射を4週間の間隔で2回行い，3か月後に右眼視力は1.0に回復した。以後6か月間，脈絡膜新生血管の再発はない。結論：卵黄状黄斑ジストロフィに伴う脈絡膜新生血管に対してベバシズマブ硝子体注射が奏効した。

Abstract.　Purpose：To report a case of vitelliform macular dystrophy treated by intavitreal bevacizumab for choroidal neovascularization. Case：A 23-year-old female presented with suddenly impaired vision in her right eye. She had been diagnosed with vitelliform macular dystrophy when seen by an ophthalmologist for ocular trauma 8 years before. Findings：Corrected visual acuity was 0.5 right and 1.2 left. The right eye showed subretinal hemorrhage in the macular area. Fluorescein angiography showed findings suggestive of choroidal neovascularization in the macula. The right eye was treated by two sessions of intravireal bevacizumab at a 4-week interval. Visual acuity in the right eye improved to 1.0 3 months later. She has been doing well for 6 months until present. Conclusion：This case illustrates that intravitreal bevacizumab may be effective for choroidal neovascularization secondary to vitelliform macular dystrophy.